In a first study of its kind, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy was found to be safe and tolerable for patients with alcohol use disorder. The treatment did not raise serious safety concerns and was well tolerated by participants, suggesting that this combined approach warrants further investigation as a potential therapy for alcohol addiction.
In an open-label feasibility study, 14 adults with alcohol use disorder who had recently completed detoxification underwent an eight-week course of ten psychotherapy sessions, including two sessions with MDMA. Bayesian analysis estimated a 55%–63% probability of a two-level reduction in World Health Organization drinking risk three months after treatment. Preliminary findings also indicated reductions in alcohol craving and improvements in sleep and aspects of psychosocial functioning at the three-month follow-up compared to baseline. The results provide initial insights into MDMA-assisted psychotherapy's potential to improve quality of life and well-being beyond reducing drinking.